Project: Novel Parkinson's Disease therapy targeting iron-related cell death and alpha synuclein aggregation
| Acronym | PD-IRONSYN (Reference Number: 114370) |
| Duration | 01/11/2020 - 01/11/2023 |
| Project Topic | We will deliver a first-in-class multifunction iron chelating compound (SP-420) as a disease-modifying therapy for Parkinson’s Disease (PD). SP-420 targets the accumulation of iron in order to reduce iron-related oxidative stress, cell death (ferroptosis) and alpha synuclein aggregation. SP-420 is considered to be superior (in efficacy and safety) to other iron chelators. Preclinical data for SP-420 as PD-therapy will be obtained, in order to start clinical testing 18 months after the project. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 13 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Abfero Ltd | Coordinator | United Kingdom |
| 2 | Centre Hospitalier Universitaire de Lille | Partner | France |
| 3 | Erasmus Medical Center | Partner | Netherlands |
| 4 | Pronexus Analytical AB | Partner | Sweden |